Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition READOUT: Deputy Undersecretary Lee visits Colombia, engages with new Petro administration leaders on labor compliance under trade agreement

Issued:  Monday 09 November 2009, London UK

GlaxoSmithKline (GSK) today announced the results from the clinical trial assessing Pandemrix, GSK’s adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix ® .  The trial showed that co-administration of one dose of both vaccines in separate arms, induced a strong response in adults for both the H1N1 pandemic vaccine as well as the seasonal vaccine. The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity of the co-administration of Pandemrix and Fluarix.

The data from this study confirm previously reported results in an elderly population, which showed that the immune response elicited by Pandemrix exceeded the immunogenicity criteria as defined by international licensing authorities for a pandemic influenza vaccine.  Additionally the subjects in this trial also demonstrated a strong immune response to the seasonal influenza vaccine, again exceeding the three immunogenicity criteria as defined by international licensing authorities for a seasonal trivalent vaccine.

“These results provide key information to public health organisations. These new data on the co-administration of both the seasonal and pandemic influenza vaccines could help simplify the influenza vaccination programmes that countries are now starting to initiate,” said Jean Stéphenne, President of GSK Biologicals. “This provides the valuable insight into vaccination in this specific age group that generally benefits from the annual seasonal vaccination.”

In this trial, 89.3% of the subjects receiving both vaccines at the same time demonstrated a response for the H1N1 virus that was above the regulatory threshold of 1:40 seroprotection, which is considered indicative of protection. The immune response for the seasonal vaccine exceeded the regulatory threshold defined by international licensing authorities for registration of the seasonal influenza vaccine each year (69.0%, 78.6% and 100% for A/Brisbane (H1N1), A/Uruguay (H3N2) and B/Brisbane respectively). The annual seasonal influenza vaccine contains 3 strains of influenza identified by public health organisations in advance of an upcoming influenza season. For the Northern Hemisphere 2009 / 2010 influenza season the composition of the seasonal influenza vaccine was determined before the appearance of the pandemic H1N1 strain.  

The tolerability of the vaccine in this study was shown to be in line with that observed in the previously EMEA approved H5N1 adjuvanted vaccine as well as in the pandemic H1N1 trials to date. Local reactions such as pain, redness, and swelling at the site of injection were observed in this trial. General reactions such as fatigue, low grade fever, headache, and muscle ache were also observed in this trial, and were similar between the group that received both vaccines at the same time to those in a comparison group receiving the adjuvanted pandemic influenza vaccine with co-administration of a placebo injection.

Further information on GSK’s development of a vaccine to protect against pandemic 2009, including explanation of the vaccine development process and background information on adjuvants is available on:

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit



UK Media enquiries:

Philip Thomson

(020) 8047 5502


Claire Brough

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Gwenan White

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839



European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill Baxter

(215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2008.

Source link